Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3344 - Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results


10 Sep 2017


Poster display session


Clinical Research;  Urothelial Cancers


Scott Tagawa


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


S.T. Tagawa1, B. Faltas1, E. Lam2, P. Saylor3, A. Bardia3, J. Hajdenberg4, A.K. Morgans5, E. Lim6, K. Kalinsky6, D.P. Petrylak7, M. Guarino8, M.D. Galsky9, P. Maliakal10, B. Mudenda10, R. Sharkey10, W. Wegener10, D. Goldenberg10

Author affiliations

  • 1 Hematology And Medical Oncology, Weill Cornell Medical College, 10065 - New York/US
  • 2 Division Of Medical Oncology, University of Colorado, Denver/US
  • 3 Medical Oncology, Massachusetts General Hospital, Boston/US
  • 4 Medical Oncology, University of Florida Health Cancer Center, Orlando/US
  • 5 Medical Oncology, Vanderbilt Ingram Cancer Center, Nashville/US
  • 6 Medical Oncology, Columbia University-Herbert Irving Comprehensive Cancer Center, New York/US
  • 7 Smilow Cancer Center, Yale University School of Medicine Medical Oncology, 06520-8032 - New Haven/US
  • 8 Helen F. Graham Cancer Center, Christiana Care Health System, Newark/US
  • 9 Department Of Medicine, Icahn School of Medicine at Mount Sinai, New York/US
  • 10 Oncology, Immunomedics, Inc., Morris Plains/US


Abstract 3344


Pts with metastatic UC have limited therapy options. Immune checkpoint inhibitors (CPI) are now given to patients with advanced UC, but only about 25% respond. We are studying the safety and efficacy of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate, in pts with UC refractory to other therapies.


In this phase I/II study (NCT01631552), pts with metastatic UC who progressed after ≥1 prior systemic therapy were treated with IMMU-132 at 10 mg/kg on days 1 and 8 of 21-day cycles, until progression or unacceptable toxicity. All intention-to-treat (ITT) pts, including those who relapsed/progressed after CPI therapy, are evaluated for safety, ORR by RECIST 1.1 (confirmed PR/CR), PFS, and OS. Response-evaluable (RE) pts received ≥ 2 doses and ≥ 1 post-baseline CT (RECIST 1.1) assessment.


41 pts (39M/2F; median age 68 y, range 50-91) were enrolled (RE = 36); ECOG 0/1: 31%/69%; median of 3 (range 1-6) prior therapies, including 34/41 platinum and 15/41 CPI regimens. Metastatic sites: lymph node 68%, lungs 54%, liver 32%, bone 27%; overall visceral disease, 31/41 (76%). Pts received a median of 12 (range 1-58) doses. ORR in the ITT population was 34% [14/41 (1 CR, 13 PR); ORR was 39% in the RE group, including 5/13 (39%) with liver mets]; 14 SD (39%); 8 PD (20%), and 5 inevaluable. In responders, 13/14 had prior platinum, 8/14 (57%) ≥3 prior therapies, and 4 prior CPI [4/13 in the RE group (31%), where IMMU-132 was ≥4th line of therapy in 11/13 pts]. Median time to response: 1.9 mos. Median duration of response: 12.9 mos (95%CI, 5.1-12.9), with 8/14 continuing therapy. Clinical benefit rate (CR+PR+SD≥6 mos) is 44%; 56% for SD ≥ 4 mos. In the 41 ITT pts, median PFS and OS are 7.2 (95% CI, 5.0-10.7) and 15.5 mos (95% CI, 8.9-17.2), respectively. Grade ≥3 adverse events ≥5% were 28% neutropenia, 9% febrile neutropenia, 9% fatigue, 9% anemia, 6% diarrhea.


With an ITT ORR of 34%, PFS of 7.2 mos, OS of 15.5 mos, and duration of response of 12.9 mos in 41 unselected pts with advanced pretreated UC (median of 3 prior therapies), these interim results show IMMU-132 is a promising agent in pts relapsed/refractory to chemotherapy and immune checkpoint inhibitors.

Clinical trial identification


Legal entity responsible for the study

Immunomedics, Inc.


Immunomedics, Inc.


S.T. Tagawa: Received honoraria for consulting from Immunomedics; Weill Cornell has received research funding from Immunomedics. B. Faltas: Weill Cornell received research funding from Immunomedics, Inc. P. Maliakal, B. Mudenda, R. Sharkey, W. Wegener, D. Goldenberg: Employed by Immunomedics, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.